[A retrospective study of amphotericin B treatment for invasive fungal infection].
To evaluate the safety, efficacy and economics of amphotericin B for the treatment of deep fungal infection. Retrospectively analyze the data from 113 cases with invasive fungal infection, who were treated with amphotericin B. The total efficacy of amphotericin B is above 76%. The incidence of hypokalemia, creatinine (Cr) and blood urea nitrogen (BUN) elevation were 33.6%, 29.0% and 27.4%, respectively. The instant side effect such as fever and etc. was seen in 15.0%. No dead cases and irreversible renal function impairment could be attributed to amphotericin B. The incidence of allergic reaction and other instant reaction declined after amphotericin B manufacture techniques improved. For standard recommended duration from major guidelines, such as infective endocarditis, osteomyelitis and meningitis, the management with amphotericin B should last at least 12 weeks. The cost for treatment with different agents, such as amphotericin B, fluconazole, itraconazole, liposomal amphotericin B (LamB), voriconazole and caspofungin acetate were RMB 4600, 38,000, 99,100, 190,000, 250,000 and 270,000 yuan, respectively. Amphotericin B is still the most effective agent for anti-fungal treatment. The incidence of allergic reaction and other instant reaction declined after amphotericin B manufacture techniques improved. Most patients can finish the treatment and be cured. Among all the anti-fungal agents, amphotericin B is still the most cost-effective medicine, especially for the patients who need long time treatment.